The global Psychiatric and Nervous Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

A psychiatric and nervous drug (psychiatric or psychotropic medication) is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system.

Mental health and well-being affect our daily lives. Psychotropic medications can be an important part of the tools available to help keep us well.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Infinity Market Research newest research report, the ?Psychiatric and Nervous Drugs Industry Forecast? looks at past sales and reviews total world Psychiatric and Nervous Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Psychiatric and Nervous Drugs sales for 2025 through 2031. With Psychiatric and Nervous Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psychiatric and Nervous Drugs industry.

This Insight Report provides a comprehensive analysis of the global Psychiatric and Nervous Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psychiatric and Nervous Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Psychiatric and Nervous Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psychiatric and Nervous Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psychiatric and Nervous Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Psychiatric and Nervous Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Antidepressants
    Anti-anxiety
    Antipsychotic
    Mood Stabilizing
    Stimulant Medications
    Others

Segmentation by Application:

    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Pfizer
    Ely Lilly
    Actavis
    Mylan
    Randox
    Intellipharmaceutics
    Astrazeneca
    Lundbeck
    Allergan
    GSK
    Otsuka Pharmaceutical
    Takeda
    NHU Group
    Shionogi
    APOTEX
    Chengdu Kanghong Pharmaceutical
    HUAHAI
    Zhejiang Jianfeng
    Beijing Winsunny Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Psychiatric and Nervous Drugs market?
What factors are driving Psychiatric and Nervous Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psychiatric and Nervous Drugs market opportunities vary by end market size?
How does Psychiatric and Nervous Drugs break out by Type, by Application?